The Number of Lymph Nodes Involved with Metastatic Disease Does Not Affect Outcome in Melanoma Patients as Long as All Disease Is Confined to the Sentinel Lymph Node
- 94 Downloads
In melanoma, a direct relationship exists between the number of nodes involved with metastatic disease and prognosis. This study was undertaken to determine whether an individual with metastatic disease confined to the sentinel lymph nodes (SLNs) would have a better prognosis than individuals with metastatic disease that has spread to the non-SLNs, regardless of the number of nodes involved.
The study group consists of 229 melanoma patients with a positive SLN who underwent regional nodal dissection. Cox proportional hazard regression models were used to assess association of the number of SLNs and non-SLNs involved with disease with overall survival (OS) and disease-free survival (DFS).
DFS and OS were unchanged regardless of how many SLNs were positive, as long as all disease was confined to SLNs. Among 183 patients without involvement of non-SLNs, OS remained the same despite an increasing number of SLNs involved (P = .59). This was true after controlling for ulceration, Breslow depth, age, sex, and adjuvant treatment. Once disease was present beyond the SLN, DFS and OS were negatively affected. Among patients with involvement of non-SLNs, there was no statistically significant association between the number of positive SLNs and survival. The risk of mortality increased with the number of non-SLNs involved with metastatic disease (P < .001).
The number of regional nodes involved with metastatic disease does not affect DFS and OS if disease is confined to the SLNs. Consideration should be given to specifying SLN versus non-SLN involvement in the American Joint Committee on Cancer staging manual.
We thank Lisa Kleis and Maureen Zimmermann for their assistance in preparation of the manuscript.
- 2.Greene FL, Page DL, Fleming ID, et al. Melanoma of the skin in AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2002. p. 209–17.Google Scholar
- 4.Houghton AN, Akerley W, Bickakjian CK, Daud A, Dilawari RA. Melanoma. NCCN clinical practice guidelines in oncology 2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf. Accessed April 13, 2009.
- 5.James JW, Reintgen D. Regional lymph node surgery for patients with malignant melanoma. In: Rigel DS, Dzubow LM, Reingen DS, Bystryn JC, Marks R, editors. Cancer of the skin. Philadelphia: Elsevier Saunders; 2005. p. 561–71.Google Scholar
- 6.Kaplan E, Meier P. Non-parametric estimation from incomplete observations. JASA. 1958;53:457–81.Google Scholar
- 7.Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. In: Gail KK, Samet JM, Tsiatis A, Wong W, editors. Statistics for biology and health. New York: Springer; 2000. p. 333–45.Google Scholar